The Effect of Beta-blockers in Substance P Levels and the Swallowing Function

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03306134

Acronym

BETASP

Enrollment

Registered

2017-10-10

Start date

2017-06-05

Completion date

2018-12-31

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Beta Blockers, Substance P, Swallowing Disorder

Brief summary

A non-randomised, prospective study to assess the effects of beta-blockers on substance P levels and the swallowing function. The study is going to be carry out in the Gastrointestinal Physiology Laboratory of the Hospital de Mataró (Spain). All participants will be actively recruited from a Linked hospital and primary care database. We include two groups: the first group (group 1) are participants taking beta-blockers and the second group (group 2) are participants not-taking beta-blockers.

Interventions

DIAGNOSTIC_TESTDysphagia

An overall assessment is going to be carry out by a multidisciplinary team during the visit. Swallowing assessment is going to be performed during the visit. We are going to use: (i) the Eating Assessment Tool (EAT-10), which is a short 10-item, easy to use, self-administered questionnaire \[4\]. Although the EAT-10 is considered to be predominantly a questionnaire on FHS, some items on HR-QoL are also included. The sum score of this 10-item questionnaire ranges from 0 to 40, and (ii) the Sydney Swallowing Questionnaire (SSQ) to clinically assess the severity of the symptoms of dysphagia, if present. All subjects are going to be submitted to the volume-viscosity swallow test (V- VST)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

\- Patients taking and not taking beta-blockers

Exclusion criteria

* Participants with heat and neck or esophageal cancer * Participants with stroke or neurological disease * Participants with central nervous system disease * Participants with concomitant treatment with Angiotensin converting enzyme inhibitors (ACEI), Angiotensin II receptor antagonists (ARA-II), Antipsychotics, Dopamine agonists, Capsaicine. * Participants with severe clinical signs of aspiration, including oxygen desaturation ≥3%.

Design outcomes

Primary

Measure	Time frame	Description
Substance P levels	1 year	In blood and saliva

Countries

Spain

Contacts

Primary ContactMarta Miarons

mmiarons@csdm.cat0034600297227

Backup ContactLaia Rofes

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026